DrugDevelopment

Unpacking Tomorrow's Cancer Fight: Key Insights from AACR 2026

A Paradigm Shift: CAR T-Cell Therapy Offers New Hope for Stiff Person Syndrome

A New Dawn for Pancreatic Cancer: Unpacking the Revolutionary Science from AACR 2026

A Renewed Sense of Hope: Roche's Ocrevus Continues to Impress in MS Care

Unlocking the Bacterial Front Door: A Breakthrough in Antimicrobial Research

The Audacious Pivot: How Kelonia Rose from the Brink to a $3 Billion Gene Therapy Vision

The Clock's Ticking: Harmony Biosciences, Wakix's Horizon, and the Path Ahead

A Digital Pioneer Departs: Andrew Baum's Exit from Pfizer

Lilly's Strategic Gambit: Unpacking the Kelonia Therapeutics Partnership

The Unlocking of a Legend: How Science Finally Conquered KRAS, the 'Undruggable' Cancer Foe

A Significant Setback: Arcus Biosciences Halts Key Lung Cancer Trial with Gilead

Pharma's Next Leap: Novo Nordisk and OpenAI Forge AI Alliance

ALX Oncology Strengthens Leadership, Welcomes Biotech Veteran Jeff Knight as Chief Development and Operating Officer

A New Era of Hope: Revolutionizing Pancreatic Cancer Treatment

A Game Changer? Allogene's 'Off-the-Shelf' CAR T Therapy Shows Stunning Promise in B-Cell Lymphoma

Telix and Regeneron Unite: A Groundbreaking Alliance for Radiopharmaceutical Innovation

A Major Boost for Alzheimer's and Parkinson's Research: Annovis Bio Secures $10 Million

The Biotech Tango: Why Merck Pumped the Brakes on Terns Pharmaceuticals' Acquisition

Avacta Marks Pivotal Moment: First Patient Dosed in AVA6103 Cancer Trial

Jasper Therapeutics Forges Ahead: A Deep Dive into 2025 Results and Future Horizons for Briquilimab

Scholar Rock's Journey: From Production Setback to Market Readiness – Why We're Still Bullish

A New Dawn Against Aging? Rubedo's RLS-1496 Shows Remarkable Promise in Eliminating 'Zombie Cells'

Quoin Pharmaceuticals Unveils Significant Clinical Progress and Strong Financial Standing for 2025

Eli Lilly's Cancer Revolution: How Loxo Oncology Reshaped an Empire

A New Dawn in Cancer Treatment: Galapagos and Gilead Unite to Battle Solid Tumors

A Deeper Look at Assembly Biosciences' Latest Financial Journey

Assembly Biosciences Navigates 2025: A Deep Dive into Financial Strategy and Groundbreaking Clinical Advances

A Game-Changer: Boost Pharma Welcomes Biotech Visionary Elaine Jones as New Board Chair

From Venom to Vital Medicine: The Unlikely Tale of the Gila Monster and Ozempic

A Glimmer of Hope: Olema Oncology Unveils Promising New Cancer Drug Data at AACR 2026

A Glimmer of Hope: Beyond Cancer's Early Clinical Results Spark Optimism

A Game-Changer in the War on Superbugs: Disarming, Not Destroying

Engene Holdings: Why 2026 Could Be Their Pivotal Moment

Vertex Pharmaceuticals Shines Bright: A Major Leap in Kidney Disease Treatment

A Glimmer of Hope for Kidney Disease: Vertex's Breakthrough in IgA Nephropathy

PROSTACT's Phase 3 Study Part 1: A Glimmer of Hope in Prostate Cancer Treatment

The FDA's Quiet Retreat: Fewer Public Debates Amid Rising Controversy

A Stinging Setback: Incyte's Cancer Therapy Fails to Clear FDA's High Bar

A Critical Eye on Progress: FDA Official Questions uniQure's Huntington's Trial Comparisons